© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The early days of HIV treatment offered only glimpses of hope. Scientists in the 1980s wrestled with daunting odds. They pushed through setbacks, guided by the suffering in communities all around the globe. Darunavir emerged from this fight, building on lessons from earlier drugs that lost their punch against drug-resistant strains. When it hit clinics in the mid-2000s, Darunavir, particularly as its ethanolate salt form, marked a major step for protease inhibitors. The story behind it is decades long—a mix of trial and error, collaborations between labs, and voices from patients determined to see better options. Real-world need drove forward every year of research and brought Darunavir to shelves.
Darunavir Ethanolate stands as a cornerstone in HIV care, mainly used alongside other antiretroviral agents. The ethanolate version helps maintain stability and aids in manufacturing, giving pills a reliable shelf life that matters not just to pharmacists but also to rural clinics stretching their resources. With a reputation for battling multi-drug-resistant HIV strains, doctors worldwide trust it for durable therapy in adults and pediatrics alike. Its protease inhibitor action blocks viral replication, a feature widely covered by clinical guides and institutional protocols.
Darunavir Ethanolate comes as a white to off-white powder or crystalline solid. You might catch a faint odor if you’re up close in a lab setting, but what really counts is its solubility profile. The ethanolate salt improves handling by slightly boosting its solubility in methanol and ethanol, sitting less comfortably in pure water. At a molecular level, it has a formula of C27H37N3O7S·C2H6O and a molecular weight just north of 593 g/mol. It doesn’t melt at standard temperatures; instead, it decomposes, so direct heating in synthesis requires careful temperature control. That matters most in the stages leading up to large-scale tablet production.
Manufacturers set strict standards for Darunavir Ethanolate’s purity and composition to satisfy international regulations. Each batch hits a minimum purity threshold of 98% by HPLC, and water content stays under 3.5% to avoid unwanted degradation during shipping or storage. Labels carry both lot numbers for traceability and explicit storage instructions: keep away from moisture, store at 20-25°C, and use desiccant packs. Names like Prezista, Prezcobix (when paired with cobicistat), or simply “Darunavir Ethanolate” appear, depending on the market or formulation. Pharmacists and clinicians look for these designations to ensure patients get precisely the right form.
Synthesizing Darunavir Ethanolate takes several steps. Start with a hydroxyethylamine sulfonamide core, and build off that foundation using stepwise protection, acylation, and deprotection techniques. One key challenge in the lab shows up while assembling the bis-tetrahydrofuran segment—a structure that helps Darunavir evade common drug resistance. Each step relies on widely available reagents under carefully controlled pH and temperatures, avoiding side reactions that could knock purity out of spec. Once the free base crystallizes, scientists treat it with excess ethanol, encouraging formation of the ethanolate salt. Full drying traps ethanol in a predictable ratio, critical for dosing accuracy in finished tablets.
Chemists keep searching for ways to tweak Darunavir’s backbone, aiming for forms that hang around in the body longer or target viruses lurking in hard-to-reach tissues. Routine derivatization experiments swap out side chains or alter the sulfonamide group; some changes show small bumps in activity or stability, others blunt effectiveness. Reductive amination, esterification, and alkylation show up frequently on lab benches chasing more patient-friendly versions. Results, though, can vary. Ethanolate remains a gold standard for daily pill use, balancing processability and absorption well enough to support track records in long-term HIV care.
Darunavir Ethanolate comes with a handful of identities: Darunavirum, TMC114, and, more casually in medical conversations, “DRV.” In the United States and Europe, the common trade name “Prezista” appears on prescription bottles for Darunavir Ethanolate. Fixed-dose combinations—like Prezcobix—combine it with a boosting agent to keep levels steady in the bloodstream. Pharmaceutical patents and regulatory filings may use detailed chemical names, but everyday clinicians and pharmacists tend to stick with trade names and abbreviations for clarity and speed.
Handling Darunavir Ethanolate requires training and respect for cleanroom protocols. Tablets carry a low risk for workers, but raw powder calls for gloves, facemasks, and well-ventilated hoods. Exposure through the skin or inhalation can bring mild irritation, which is why workstations stay clean and monitored. Spills get contained quickly, and disposal routes follow both local and international hazardous waste rules. Finished product packaging goes through rigorous inspection to block counterfeit entries in the supply chain. Inside hospitals, pharmacists double-check expiry dates and storage conditions daily, a basic but crucial habit that keeps patients safe.
Darunavir Ethanolate sees heavy use in combination antiretroviral therapy for HIV-1 infection, especially for those who have tried several regimens already. Infectious disease doctors lean on its record when patients show resistance to earlier drugs, tailoring therapy based on resistance testing. Pediatric formulations now reach children in regions once shut out from high-quality care, thanks to global health initiatives. On a wider scale, non-profit distributors supply it at reduced cost to lower-income regions battling rising HIV rates, often working with local clinics to train pharmacists and nurses on proper use. Government programs lay out clear protocols to avoid supply gaps and support ongoing adherence campaigns.
Big efforts in R&D centers target new forms of Darunavir Ethanolate, aiming for slow-release injectables and pills that suit patient lifestyles better. Some studies go after ways to minimize side effects—liver monitoring stands front-and-center due to early warning data from post-marketing surveillance. Collaborative efforts with academic labs explore combination therapies that could squeeze more out of existing drugs. Real-world evidence keeps shaping future versions, as researchers regularly talk to front-line doctors and patients about pill fatigue, supply barriers, and local patterns of resistance. Data from ongoing trials feeds back into public guidelines, reflecting a cycle that pushes forward based on collective experience and stubborn real-world problems.
Look at toxicity data, and you’ll see Darunavir Ethanolate compares favorably to some earlier protease inhibitors. Common threads run through studies: highest concern centers on liver enzyme elevations, rare cases of hypersensitivity, and interactions with drugs processed through the liver’s enzyme system. Toxicologists run screens using both animal models and patient registries, tracking patterns from mild headaches to more serious liver drops. Frontline clinics rely on lab tests to spot trouble early, and education campaigns remind patients about warning signs. Pharmaceutical companies keep supporting new safety studies, as rare side effects can surface with broader, longer use. Post-marketing surveillance remains a crucial layer of protection for everyone who depends on these therapies.
Researchers and doctors do not stand still with Darunavir Ethanolate. Advocacy circles call for forms easier to store, deliver, and swallow—especially in settings without reliable fridges or in populations with swallowing issues. New tablet coatings and simplified dosing schedules could ease the routine for both patients and care teams. Efforts in precision medicine hope to design regimens tuned to each person’s viral genetics, potentially squeezing even better results from existing drugs like Darunavir Ethanolate. The global health stage waits for breakthroughs that reduce dependency on daily pills, possibly through injectable slow-release forms or nano-formulations that reach tricky reservoirs in the body. Funding for these developments continues through public and private partnerships, as everyone—scientists, patients, policymakers—pushes for longer, healthier lives for people living with HIV.
Darunavir ethanolate plays a huge role in helping people living with HIV manage their day-to-day health. Every day, I meet folks who depend on it to hold back the virus that, unchecked, could devastate their immune systems. This isn’t some niche medication. Clinics, pharmacies, and medical teams around the globe rely on it because it stands up well against tough strains of HIV. Since HIV works fast and adapts, doctors need medicines that can keep pace. Darunavir ethanolate offers a strong shield where older drugs sometimes fall short.
HIV teaches you a lot about perseverance and patience. People using darunavir ethanolate know the drill: time the doses, stick to a routine, and get regular bloodwork. The medicine stops the virus from copying itself inside the body. That means fewer sick days, reduced risk of passing HIV to others, and a shot at a normal lifespan. Patients tell me about feeling safer and more hopeful when their virus levels come back undetectable after months on this treatment. Darunavir ethanolate brings that peace of mind.
Drug resistance in HIV isn’t just a doctor’s worry—it’s something that keeps patients up at night. Over time, the virus can find ways to dodge certain medicines. Darunavir ethanolate gives doctors another tool, because it’s built to fight forms of the virus that have figured out workarounds to earlier drugs. And this isn’t just theory. A study published in the Journal of Infectious Diseases showed darunavir’s effectiveness against resistant strains, which lets people stay on top of their treatment instead of scrambling for a new plan.
No medicine works for everyone without a hitch. People sometimes feel nauseous or get skin rashes. Some patients report headaches or diarrhea. It takes adjustments, sometimes switching other medicines around or managing minor issues with food and fluids. The best doctors I know listen closely to their patients’ stories and tweak the treatment to make it work. The CDC provides updated guidance on managing side effects and potential interactions, so medical teams aren’t flying blind.
A problem that comes up in clinics and support groups involves access. Insurance paperwork, policy restrictions, and plain old cost often stand in the way of consistent treatment. Even in developed countries, patients run into obstacles at the pharmacy counter. Advocacy groups keep pushing for lower drug prices and wider coverage, and that pressure matters. Peer support networks help people keep up with complicated regimens and fight stigma, but the system needs more investment in outreach and education.
Sticking with a routine, getting expert advice, and keeping up with lab visits form the foundation of successful HIV care. Newer versions and combinations continue to arrive, making things easier for people managing HIV, but darunavir ethanolate remains a reliable choice. Public health efforts can create smoother paths by expanding access, providing clear info, and training more healthcare providers in up-to-date HIV care. Living with HIV takes resilience, and darunavir ethanolate gives people one more tool to build a better future.
Doctors prescribe Darunavir Ethanolate to help people living with HIV manage their health. People often start searching for what to expect when a new medication gets added to their daily routine. Every pill comes with a story, especially in treatments as vital as antiretrovirals. Most folks hope for better health, but it helps to recognize some trade-offs along the way. Based on what I’ve seen in clinic settings and what’s published in peer-reviewed journals, some side effects tend to pop up more often than others. Nobody wants surprises after that first prescription is filled.
Stomach issues rank high for folks taking Darunavir Ethanolate. A wave of nausea can hit, especially in the first few days. There might be some loose stools, an unsettled stomach, or a need to make extra trips to the bathroom. Fatigue can follow since dehydration sometimes sneaks in with diarrhea. Sometimes folks end up skipping meals or taking extra care with what food goes down. Cramping and gas aren’t rare either. Patients who drink enough water and stick to small, healthy meals often find these problems fade over weeks.
Many people talk about headaches after starting Darunavir Ethanolate. Some days the pain lingers at the temples; other days, it rises behind the eyes. Lightheadedness steps in at times, making it harder to concentrate at work or on daily tasks. Talking to people who use this drug regularly, some mention that headaches drop off after a few weeks, while others still need to reach for over-the-counter relief. Tracking headaches with a small notebook has helped patients bring solid details to their doctor visits, making tweaks to other medicines or daily habits easier.
Several patients have reported new rashes or itching on their arms, chest, or back. While most reactions seem mild, rare cases look more serious. Some skin problems hint at allergies or a need for a new prescription. Telling the doctor right away speeds up solutions—sometimes changing soaps or laundry products, other times picking a different drug. I always encourage anyone with sudden rash to take photos and keep in touch with their care team.
Liver health comes into play with Darunavir Ethanolate. Studies report some people see bumps in their liver enzyme tests. While most don’t “feel” a liver problem, regular bloodwork gives a heads-up before it gets serious. Extra caution matters for people with hepatitis or past liver issues. Sometimes doctors spot minor changes and it’s status quo, other times they recommend closer monitoring or change the dose. Bringing all other prescriptions and supplements to the appointment lets the care team double-check for risky combinations.
Lab work sometimes shows higher cholesterol levels or a bump in blood sugar. People who take this drug long-term see value in eating healthier food and squeezing in extra walks during the week. Some patients also start blood pressure or cholesterol medicine to protect their heart. Keeping a close eye on bloodwork helps doctors catch trends before they turn into big problems, which flags the importance of sticking with regular checkups.
People who talk openly about side effects get relief sooner. Recording any new health change between visits makes it easier to track what’s working and what’s not. Joining support groups or talking to a pharmacist can give new ideas for symptom relief, too. The best care comes when everyone—doctor, pharmacist, and patient—shares information. The journey with Darunavir Ethanolate rarely feels the same for any two people, but staying alert to these side effects builds confidence and safety along the way.
For a lot of people living with HIV, sticking to the prescribed medicine makes a huge difference in staying healthy and keeping the virus in check. Darunavir Ethanolate has proven itself as a game-changer in antiretroviral therapy, helping many avoid complications and live full lives. Missing out on important details, like how and when to take this medicine, could mean the difference between clean lab results and a call from the doctor to change your routine.
Experience tells me that even a simple tablet can turn complicated if we don't follow the rules. Darunavir Ethanolate works best when swallowed whole with food, not crushed up or taken on an empty stomach. Food helps raise the amount of medicine the body absorbs, which means better virus control and fewer nasty surprises with your test results. Skipping this step could mean the medicine doesn’t work as it should, leaving a person open to the virus sneaking past the body’s defenses.
It’s not just about Darunavir Ethanolate on its own. Doctors almost always prescribe it along with another medicine called ritonavir. Ritonavir helps boost the strength of Darunavir Ethanolate in the body, making it last longer and work harder against the virus. If someone forgets to take one or the other, or takes them at different times, both medicines lose their punch. From what I've seen in clinics, those who skip ritonavir wind up with weaker results and sometimes see resistant strains of HIV pop up.
Daily routines can throw anybody off track, whether you work shifts or juggle family duties. But no matter how busy things get, missing doses often leads to bigger problems. HIV doesn’t take breaks and neither should treatment. Setting reminders, tying doses to regular meals, or getting family involved can make it easier to stick with the plan. I've known people who use pillboxes or phone alarms to remind them every single day, and that small effort can mean months or years of good health down the road.
Sometimes, the honest truth is that side effects scare people off. Stomach upset, diarrhea, and rash came up more than once among folks I’ve met. Instead of skipping doses or stopping, reaching out to doctors or pharmacists makes a big difference. Those health pros can suggest ways to ease the discomfort—switching meal times or trying new foods, for example. Open communication lets people solve problems early, before they decide to quit on their own.
Life changes fast, and so do health needs. Regular check-ins with a doctor keep the focus sharp, making sure the treatment still works and catching side effects before they grow. Some folks try to save time by skipping these visits, but that usually backfires. Doctors can change doses or adjust medications if something isn't right. For anyone on Darunavir Ethanolate, close communication with healthcare providers adds up to better health and fewer surprises along the way.
Pregnancy often turns daily routines upside down, especially when health concerns collide with serious illnesses. HIV is one of those challenges that pushes families to seek clear answers and dependable solutions. Among the medicines used to treat HIV, Darunavir Ethanolate stands out as a potent antiretroviral drug. Questions about its use during pregnancy carry real weight, since the well-being of both mother and developing baby hang in the balance.
Darunavir Ethanolate has a strong reputation for suppressing HIV and helping people live longer, healthier lives. For many mothers, the ultimate goal is safe delivery and protecting their child from acquiring the virus. According to research published in medical journals and guidance from groups like the World Health Organization, Darunavir, teamed with other drugs in a regimen, has shown positive results. Yet, pregnancy adds another dimension. The body’s metabolism changes by the week, which can affect how medicines move through the system.
Studies tracking mothers exposed to Darunavir-based regimens do not signal alarming rates of birth defects or toxicities compared to other antiretrovirals. Some evidence shows that using Darunavir in pregnancy doesn't increase risk of major congenital problems. Pregnant women diagnosed with HIV have had successful outcomes when this medication is part of their treatment, especially with early monitoring and the right support.
Doctors like to say no drug is completely risk-free, especially for expectant mothers. Everything from morning sickness to how the placenta handles medication can matter. There are reports that certain HIV medicines could impact the baby's growth or chemistry, which means extra vigilance makes all the difference. Close monitoring with regular blood work and ultrasound helps to spot any hiccups before they grow into bigger problems.
Relying on Darunavir isn’t just about sticking to a chart or protocol. Providers face situations where women come into clinics late in pregnancy or already have resistance to other medicines. In my own experience supporting families through HIV care, the need for flexibility is constant. Pregnant women often have concerns beyond the numbers and labs—they want reassurance about side effects and long-term impacts on their child.
The Food and Drug Administration gives Darunavir a pregnancy classification that signals caution: there is not enough evidence from human studies to guarantee complete safety. Animal studies don’t suggest severe toxicity, but experts avoid complacency. They weigh options based on the severity of the mother’s illness, her immune status, and available drug options. If switching to another regimen won't work—or could risk the mother’s life—using Darunavir may make sense.
Keeping communication open helps patients weigh the benefits against any concerns. Pregnant women with HIV deserve the same shot at a healthy outcome, which sometimes means accepting the best available evidence rather than waiting for perfect data. Antenatal clinics need funding for close follow-up, and mothers must get honest answers and choices, not just checklists or quick fixes.
The global picture shows more women getting access to HIV treatment, including Darunavir-based combinations. Investment in real-world data collection will push knowledge ahead. Future solutions should focus on tailored counseling, clear risk assessment, and ensuring every mother has access to the medicines—and the monitoring—she needs, so no one gets left behind because answers aren't easy.
Darunavir Ethanolate belongs to a group of medicines that fight off HIV. Doctors usually combine this drug with others to help people living with HIV keep the virus under control. No medicine works in isolation, and Darunavir Ethanolate brings along some baggage. Treating HIV demands responsibility—skipping doses or missing check-ins may give the virus a chance to come roaring back. I’ve watched people battle with the strict routine that comes with antiviral drugs, and sticking to it can be tough, but necessary.
Before doctors start folks on Darunavir Ethanolate, they often run a series of blood tests. The liver takes the lead in processing this drug, so any sign of liver trouble—like hepatitis or cirrhosis—means doctors have to think carefully. Doctors also ask about allergies and past reactions. A handful of patients may react to sulfa drugs, so it pays to share that history up front. Talking about every medicine and supplement you take, even the herbal ones, helps flag up any risky combinations.
Even with close supervision, side effects sneak in. Some, like headache, nausea, or diarrhea, wear you down. Rash pops up in some folks. Swelling in the face or trouble breathing needs attention right away. I’ve seen people underestimate mild symptoms, only to wind up in a worse state. Keeping a diary of changes helps spot patterns your doctor should know about.
Darunavir Ethanolate holds a long list of “do not combine” warnings. Mixing with drugs for cholesterol, seizures, or heart rhythm won’t end well. Grapefruit juice sounds harmless, but it can mess up the way this drug breaks down, so steering clear matters. Alcohol doesn’t help either, with the liver already working hard.
Antacids and supplements may also change how the medicine is absorbed. Best to keep a written list of everything you take, sharing it at every doctor’s visit. Getting prescriptions filled at one pharmacy makes tracking problems easier.
Managing an HIV drug routine takes money and time. Insurance paperwork can sap your energy. Some pharmacies work with patient-assistance programs, so asking for help eases the financial sting. Issues of stigma still make some people hide their treatment, which only puts health at risk. Support means more than just medicine—it’s about friends, privacy, and respect.
Setting alarms or phone reminders helps keep doses on time. Refilling prescriptions before you run out means you’ll never miss a dose. Blood work feels like a chore, but without those check-ins, you lose sight of how things stand inside the body. If you travel, keep meds in your carry-on; lost luggage leaves you with nothing to manage the virus.
Doctors, nurses, and pharmacists want honest conversations. Speak up if something feels off. No one should feel left in the dark about side effects, dose timing, or food choices. If one treatment stops working, other options may fit better.
Taking Darunavir Ethanolate doesn’t just mean swallowing a pill. It calls for attention, honesty, and teamwork. The goal stays the same: keeping the virus at bay so life rolls on with as few bumps as possible.
| Names | |
| Preferred IUPAC name | (2S,3R)-1-(4-aminophenyl)sulfonyl-2-[(1S,2R)-3-[[(4-carbamoylphenyl)amino]carbonyl]-2-hydroxy-1-phenylpropyl]amino]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; ethanol |
| Other names |
TMC114 Prezista Darunavirum UNII-LYG9412GRN CGP73547A |
| Pronunciation | /dəˌruː.nəˈvɪr iˈθæn.ə.leɪt/ |
| Identifiers | |
| CAS Number | 206361-99-1 |
| Beilstein Reference | 3682561 |
| ChEBI | CHEBI:685122 |
| ChEMBL | CHEMBL1201193 |
| ChemSpider | 11370808 |
| DrugBank | DB01264 |
| ECHA InfoCard | The ECHA InfoCard for Darunavir Ethanolate is **"1000410-95-6"**. |
| EC Number | EC 3.4.23.49 |
| Gmelin Reference | 1176373 |
| KEGG | D01817 |
| MeSH | D000072633 |
| PubChem CID | 10184653 |
| RTECS number | YV5551200K |
| UNII | H7SD4E1YKD |
| UN number | UN3241 |
| Properties | |
| Chemical formula | C27H37N3O7S·C2H6O |
| Molar mass | 547.68 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 0.93 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 2.2 |
| Acidity (pKa) | 13.33 |
| Basicity (pKb) | 2.75 |
| Magnetic susceptibility (χ) | -80.0e-6 cm³/mol |
| Refractive index (nD) | 1.583 |
| Dipole moment | 6.05 ± 0.5 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.2 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -201.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | Std enthalpy of combustion (ΔcH⦵298) of Darunavir Ethanolate is -14210 kJ/mol |
| Pharmacology | |
| ATC code | J05AE10 |
| Hazards | |
| Main hazards | May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS05,GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P261, P273, P280, P305+P351+P338, P337+P313 |
| Flash point | 94.6 °C |
| Lethal dose or concentration | Lethal dose or concentration: LD50 (rat, oral): >2000 mg/kg |
| LD50 (median dose) | Greater than 1,000 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL (Permissible) of Darunavir Ethanolate: Not established |
| REL (Recommended) | 800 mg once daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Amprenavir Fosamprenavir Indinavir Lopinavir Nelfinavir Ritonavir Saquinavir Atazanavir Tipranavir |
